52-Week High
$89.48
52-Week Low
$72.30
Market Cap
$48.5B
P/E Ratio
46.49
Div Yield
N/A

Edwards Lifesciences Performance Comparison

Loading chart data...

Stock Range

Today's Range

Low: $84.61 High: $86.31
on June 15, 2026

52 Week Range

Low: $72.30 High: $89.48
on October 13, 2025
on June 5, 2026

All-Time High: $131.73 on December 27, 2021

Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights

Key Statistics

Market Cap i $48.5B
EPS i 1.81
P/E Ratio (TTM) i 46.49
Forward P/E i 25.05
P/B Ratio i 4.73
PEG Ratio i -0.62
Div. Yield i N/A
ROE i 10.38%
Beta i 0.945
Debt to Equity i 6.82

Join Our United States Telegram Channel

Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!

Financial Highlights

Quarter Income Flow i

Annual Income Flow i

Peer Performance Comparison

Company Market Cap 1W 1M 3M 6M YTD 1Y 3Y 5Y 10Y 15Y 20Y
48.52B Large-cap 0.50% 6.02% 3.26% 3.48% 1.11% 13.25% -7.43% -15.49% 159.09% 507.93% 2,151.59%
160.70B Large-cap -2.02% 4.97% -19.35% -30.98% -28.60% -34.98% -16.97% -20.08% 135.84% 255.56% 329.52%
126.25B Large-cap 2.13% 0.38% -11.91% -13.33% -11.56% -17.25% 6.06% 22.47% 172.95% 440.98% 592.85%
107.58B Large-cap -0.38% 5.55% -8.91% -18.45% -16.31% -8.10% -10.04% -34.92% -4.68% 110.00% 59.60%
97.63B Large-cap -3.98% -11.24% -33.00% -49.28% -50.63% -52.97% -13.64% 9.04% 108.58% 590.87% 133.50%
Dexcom
Dexcom DXCM
23.76B Large-cap -3.13% 20.43% 11.88% 12.92% 11.54% -8.07% -42.07% -27.92% 315.26% 2,149.85% 2,129.88%

Ownership & Short Interest

Insider Ownership i 0.17%
Institutional Ownership i 92.88%
Shares Short i 9M
Short Ratio i 2.05
Short % of Shares Outstanding i 1.84%
Average 10-Day Volume i 6M
Average 90-Day Volume i 5M

Calculate Your Edwards Lifesciences Investment Returns

$

Long-Term Investment Performance Analysis

Edwards Lifesciences stock price in Jul 2016 was $35.42, A $1,000.00 lump sum investment in Edwards Lifesciences made 9 years ago would be worth approximately $2,435.91 today, representing a strong return of 143.59%. This translates to an annualized return (CAGR) of 9.40%.

9 Years 10 Months Investment Scenario (Jul 2016 - Jun 2026)

Initial Investment $1,000.00
Current Value $2,435.91
Annual Return (CAGR) 9.40%
Shares Owned 28.2

Investment Breakdown

Value Comparison

Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.

Frequently Asked Questions

In the last 52 weeks, Edwards Lifesciences reached a high of $89.48 (on June 5, 2026) and a low of $72.30 (on October 13, 2025).
Curious about Edwards Lifesciences's size and valuation? Its market capitalization stands at 48.52B. When it comes to valuation, the P/E ratio (trailing twelve months) is 46.49, and the forward P/E (looking ahead) is 25.05.
As for dividends, Edwards Lifesciences isn't currently offering a significant yield, or that specific data isn't available right now.

When looking at Edwards Lifesciences, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

CompanyMkt CapSectorIndustry1Y Return3Y Return
Abbott Laboratories
ABT
160.70BHealthcareMedical Devices-34.98%-16.97%
Stryker
SYK
126.25BHealthcareMedical Devices-17.25%6.06%
Medtronic plc
MDT
107.58BHealthcareMedical Devices-8.10%-10.04%
Boston Scientific
BSX
97.63BHealthcareMedical Devices-52.97%-13.64%
Dexcom
DXCM
23.76BHealthcareMedical Devices-8.07%-42.07%

For a more comprehensive list, please see the Peer Performance Comparison table on this page.

To get a sense of Edwards Lifesciences's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 10.38%, the Debt to Equity ratio from the most recent quarter is 6.82, and its Gross Profit Margin stands at 78.15%.
Looking at Edwards Lifesciences's growth, its revenue over the trailing twelve months (TTM) was $6B. Compared to the same quarter last year (YoY), quarterly revenue grew by 16.70%, and quarterly earnings saw a YoY growth of 6.30%.
Wondering who owns Edwards Lifesciences stock? Company insiders (like executives and directors) hold about 0.17% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 92.88%.

For more common questions about our data, please visit our About Data page.

Nippun Rana

Nippun Rana

Chasing the market trend!

Hi, I’m Nippun, a tech enthusiast from Haryana, India. I have been coding since 2010 and using my coding skills in the share market since 2020. I have been coding scripts in Pinescript that work on Tradingview app/web. I love learning about new technology and applying it to solve real-world problems. Coding and share-market are my passions, and I enjoy finding and fixing bugs in code. I aim to share my skill set and experience that can positively impact society. Feel free to connect with me, an...

Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.